PDCD1 and urinary bladder cancer: Recent clinical trials show that blockage of PD-1/PD-L1 pathway with anti-PD-1 or anti-PD-L1 antibodies can produce durable remission in several different malignancies including, but not limited to, melanoma, lung, renal and bladder cancer[11–14].